Phillips Courtney Sells 2,012 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Key Points

• Insider sale: Phillips Courtney sold 2,012 Maze Therapeutics shares for approximately $52,332, reducing their position by 22.31% to 7,007 shares. The transaction was made to cover tax withholding tied to vested equity awards.
• Stock and financial performance: MAZE recently traded at $26.21, below its 50-day and 200-day moving averages, and remains loss-making with quarterly EPS of negative $0.76.
• Analyst outlook: Despite recent insider selling and technical weakness, analyst sentiment remains broadly positive, with a consensus “Buy” rating and an average price target of $66.00.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Phillips Courtney sold 2,012 shares of Maze Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider owned 7,007 shares of the company's stock, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

• On Wednesday, September 2nd, Phillips Courtney sold 1,981 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $52,437.07.

Maze Therapeutics Price Performance

MAZE traded up $0.34 during trading on Friday, hitting $26.21. The company's stock had a trading volume of 273,266 shares, compared to its average volume of 637,671. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. The firm's 50 day moving average price is $28.74 and its two-hundred day moving average price is $31.20. Maze Therapeutics, Inc. has a 12 month low of $14.27 and a 12 month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). Sell-side analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Maze Therapeutics

Several large investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. boosted its stake in Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock valued at $150,182,000 after acquiring an additional 465,641 shares during the last quarter. TRV GP IV LLC bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $133,502,907. ARCH Venture Management LLC acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at $122,983,582. BlackRock Inc. acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics in the 2nd quarter worth $101,764,000.

Maze Therapeutics News Roundup

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. TD Cowen upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. BTIG Research restated a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Maze Therapeutics has an average rating of "Buy" and a consensus price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source